Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flupentixol is a first-generation (typical) antipsychotic of the thioxanthene class. It is primarily used for the maintenance therapy of chronic schizophrenia, especially in patients with poor compliance or frequent relapses, and can be administered as a long-acting injection or oral tablet. At lower doses, it is also prescribed for depression with or without anxiety. The drug acts mainly as an antagonist at dopamine D1 and D2 receptors with equal affinities and has additional antagonistic activity at alpha-1 adrenoceptors and serotonin 5-HT2A/2C receptors. Its antipsychotic effects are attributed to dopamine receptor blockade in the brain's mesolimbic and mesocortical pathways; antidepressant effects may relate to serotonergic antagonism. Flupentixol also exhibits weak anticholinergic and adrenergic properties, mild sedative actions, anxiolytic effects, antiemetic activity, and can cause extrapyramidal side effects at higher doses[1][4][5][6][8]. **Developers:** Lundbeck **Primary Indication:** Schizophrenia
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flupentixol.